Search

Your search keyword '"Doll, Mark A."' showing total 591 results
Start Over Author "Doll, Mark A."
591 results on '"Doll, Mark A."'

1. Architecture Proposal for 6G Systems Integrating Sensing and Communication

Author

Gersing, Peter, Doll, Mark, Huschke, Joerg, and Holschke, Oliver

Subjects
Computer Science - Networking and Internet Architecture, 68M10, C.2.1
Abstract

Integrating sensing functionality into 6G communication networks requires some changes to existing components as well as new entities processing the radar sensing signals received by the communication antennas. This whitepaper provides a comprehensive overview of the 6G design proposal for ISaC (Integrated Sensing and Communication). The whitepaper has been created by the architecture group of the KOMSENS-6G project. It represents an intermediate state of the work, as the KOMSENS-6G project is still ongoing. The proposal should serve as a basis for further discussions and alignment across innovative 6G projects., Comment: 13 pages, 14 figures, 1 table

Published
2024

4. Reinforcement learning for Admission Control in 5G Wireless Networks

Author

Raaijmakers, Youri, Mandelli, Silvio, and Doll, Mark

Subjects
Computer Science - Networking and Internet Architecture, Computer Science - Machine Learning, Electrical Engineering and Systems Science - Signal Processing
Abstract

The key challenge in admission control in wireless networks is to strike an optimal trade-off between the blocking probability for new requests while minimizing the dropping probability of ongoing requests. We consider two approaches for solving the admission control problem: i) the typically adopted threshold policy and ii) our proposed policy relying on reinforcement learning with neural networks. Extensive simulation experiments are conducted to analyze the performance of both policies. The results show that the reinforcement learning policy outperforms the threshold-based policies in the scenario with heterogeneous time-varying arrival rates and multiple user equipment types, proving its applicability in realistic wireless network scenarios.

Published
2021

19. Expression of Ceramide Synthases in Mice and Their Roles in Regulating Acyl-Chain Sphingolipids: A Framework for Baseline Levels and Future Implications in Aging and Disease

Author

Richardson, Whitney J., primary, Humphrey, Sophia B., additional, Sears, Sophia M., additional, Hoffman, Nicholas A., additional, Orwick, Andrew J., additional, Doll, Mark A., additional, Doll, Chelsea L., additional, Xia, Catherine, additional, Hernandez-Corbacho, Maria, additional, Snider, Justin M., additional, Obeid, Lina M., additional, Hannun, Yusuf A., additional, Snider, Ashley J., additional, and Siskind, Leah J., additional

Published
2023
Full Text
View/download PDF

26. Expression of Ceramide Synthases in Mice and Their Roles in Regulating Acyl-Chain Sphingolipids: A Framework for Baseline Levels and Future Implications in Aging and Disease

Author

Richardson, Whitney J., Humphrey, Sophia B., Sears, Sophia M., Hoffman, Nicholas A., Orwick, Andrew J., Doll, Mark A., Doll, Chelsea L., Xia, Catherine, Hernandez-Corbacho, Maria, Snider, Justin M., Obeid, Lina M., Hannun, Yusuf A., Snider, Ashley J., and Siskind, Leah J.

Abstract

Sphingolipids are an important class of lipids present in all eukaryotic cells that regulate critical cellular processes. Disturbances in sphingolipid homeostasis have been linked to several diseases in humans. Ceramides are central in sphingolipid metabolism and are largely synthesized by six ceramide synthase (CerS) isoforms (CerS1–6), each with a preference for different fatty acyl chain lengths. Although the tissue distribution of CerS mRNA expression in humans and the roles of CerS isoforms in synthesizing ceramides with different acyl chain lengths are known, it is unknown how CerS expression dictates ceramides and downstream metabolites within tissues. In this study, we analyzed sphingolipid levels and CerS mRNA expression in 3-month-old C57BL/6J mouse brain, heart, kidney, liver, lung, and skeletal muscle. The results showed that CerS expression and sphingolipid species abundance varied by tissue and that CerS expression was a predictor of ceramide species within tissues. Interestingly, although CerS expression was not predictive of complex sphingolipid species within all tissues, composite scores for CerSs contributions to total sphingolipids measured in each tissue correlated to CerS expression. Lastly, we determined that the most abundant ceramide species in mouse tissues aligned with CerS mRNA expression in corresponding human tissues (based on chain length preference), suggesting that mice are relevant preclinical models for ceramide and sphingolipid research.SIGNIFICANCE STATEMENTThe current study demonstrates that ceramide synthase (CerS) expression in specific tissues correlates not only with ceramide species but contributes to the generation of complex sphingolipids as well. As many of the CerSs and/or specific ceramide species have been implicated in disease, these studies suggest the potential for CerSs as therapeutic targets and the use of sphingolipid species as diagnostics in specific tissues.

Published
2024
Full Text
View/download PDF

27. Initial Access, RRC and Mobility

Author

Ericson, Mårten, primary, Spapis, Panagiotis, additional, Säily, Mikko, additional, Pedersen, Klaus, additional, Qi, Yinan, additional, Barati, Nicolas, additional, Svensson, Tommy, additional, Shariat, Mehrdad, additional, Giordani, Marco, additional, Mezzavilla, Marco, additional, Doll, Mark, additional, Miao, Honglei, additional, and Zhou, Chan, additional

Published
2018
Full Text
View/download PDF

28. RAN Architecture

Author

Marsch, Patrick, primary, Nikaein, Navid, additional, Doll, Mark, additional, Chen, Tao, additional, and Pateromichelakis, Emmanouil, additional

Published
2018
Full Text
View/download PDF

35. Association between cigarette smoking and ovarian reserve among women seeking fertility care

Author

Oladipupo, Islamiat, primary, Ali, T’shura, additional, Hein, David W., additional, Pagidas, Kelly, additional, Bohler, Henry, additional, Doll, Mark A., additional, Mann, Merry Lynn, additional, Gentry, Adrienne, additional, Chiang, Jasmine L., additional, Pierson, Rebecca C., additional, Torres, Sashia, additional, Reece, Emily, additional, and Taylor, Kira C., additional

Published
2022
Full Text
View/download PDF

39. Directional Measurements and Propagation Models at 28 GHz for Reliable Factory Coverage

Author

Chizhik, Dmitry, primary, Du, Jinfeng, additional, Valenzuela, Reinaldo A., additional, Samardzija, Dragan, additional, Kucera, Stepan, additional, Kozlov, Dmitry, additional, Fuchs, Rolf, additional, Otterbach, Juergen, additional, Koppenborg, Johannes, additional, Baracca, Paolo, additional, Doll, Mark, additional, Rodriguez, Ignacio, additional, Feick, Rodolfo, additional, and Rodriguez, Mauricio, additional

Published
2022
Full Text
View/download PDF

47. Deletion of arylamine N ‐acetyltransferase 1 in MDA‐MB‐231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis

Author

Doll, Mark A., primary, Ray, Andrew R., additional, Salazar‐González, Raúl A., additional, Shah, Parag P., additional, Vega, Alexis A., additional, Sears, Sophia M., additional, Krueger, Austin M., additional, Hong, Kyung U., additional, Beverly, Levi J., additional, and Hein, David W., additional

Published
2022
Full Text
View/download PDF

50. Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity.

Author

Orwick, Andrew, Sears, Sophia M., Sharp, Cierra N., Doll, Mark A., Shah, Parag P., Beverly, Levi J., and Siskind, Leah J.

Subjects
KIDNEY injuries, NEPHROTOXICOLOGY, RENAL cancer, RENAL fibrosis, DISEASE risk factors
Abstract

Patients with cancer represent a unique patient population with increased susceptibility to kidney disease. Drug-induced acute kidney injury (AKI) in patients with cancer is a common problem. Cisplatin is a highly effective treatment used in many solidorgan cancers and causes AKI in 30% of patients, increasing the risk of chronic kidney disease development. Most preclinical cisplatin toxicity studies have been completed in mice without cancer. We believe that the physiology of patients with cancer is not adequately represented in preclinical models, and the objective of this study was to determine how lung cancer will alter the nephrotoxicity of cisplatin. A genetically engineered mouse model and a syngeneic xenograft model of lung cancer were used. Mice were divided into the following four groups: 1) noncancer/vehicle, 2) noncancer/cisplatin, 3) cancer/vehicle, and 4) cancer/cisplatin. Mice were administered cisplatin via intraperitoneal injection once a week for 4 wk. Animals were euthanized 72 h following their final cisplatin injection. Mice with lung cancer had increased renal toxicity, injury, and fibrosis following repeated low doses of cisplatin. In addition, lung cancer alone induced kidney injury and fibrosis in the kidney before cisplatin treatment. In conclusion, this is the first study that we are aware of that assesses the impact of cancer on the kidney in conjunction with the nephrotoxicity of cisplatin. We believe that cancer is providing the first hit to the kidney and the subsequent damage from repeated doses of cisplatin becomes unsurmountable, leading to AKI and progression to chronic kidney disease. NEW & NOTEWORTHY Patients with cancer have impaired kidney function and increased susceptibility to nephrotoxic agents. Cisplatin is a commonly used chemotherapeutic with nephrotoxicity as the dose-limiting side effect. Cisplatin nephrotoxicity is almost exclusively studied in mice without cancer. Our current preclinical models do not adequately represent the complexity of patients with cancer. This study demonstrates increased renal toxicity, injury, and fibrosis in mice with lung cancer, which is exacerbated with cisplatin treatment. These results highlight the necessity of using preclinical models that more accurately capture the altered physiology of patients with cancer treated with cisplatin. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results